The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery<subtitle>A Meta-analysis of 4 Randomized Double-blind Studies</subtitle>
Abstract
BACKGROUND: Orthopedic surgery remains a condition at high risk of venous thromboembolism (VTE). Fondaparinux, the first of a new class of synthetic selective factor Xa inhibitors, may further reduce this risk compared with currently available thromboprophylactic treatments. METHODS: A meta-analysis of 4 multicenter, randomized, double-blind trials in patients undergoing elective hip replacement, elective major knee surgery, and surgery for hip fracture (N = 7344) was performed to determine whether a subcutaneous 2.5-mg, once-daily regimen of fondaparinux sodium starting 6 hours after surgery was more effective and as safe as approved enoxaparin regimens in preventing VTE. The primary efficacy outcome was VTE up to day 11, defined as deep vein thrombosis detected by mandatory bilateral venography or documented symptomatic deep vein thrombosis or pulmonary embolism. The primary safety outcome was major bleeding. RESULTS: Fondaparinux significantly reduced the incidence of VTE by day 11 (182 [6.8%] of 2682 patients) compared with enoxaparin (371 [13.7%] of 2703 patients), with a common odds reduction of 55.2% (95% confidence interval, 45.8% to 63.1%; P<.001); this beneficial effect was consistent across all types of surgery and all subgroups. Although major bleeding occurred more frequently in the fondaparinux-treated group (P =.008), the incidence of clinically relevant bleeding (leading to death or reoperation or occurring in a critical organ) did not differ between groups. CONCLUSION: In patients undergoing orthopedic surgery, 2.5 mg of fondaparinux sodium once daily, starting 6 hours postoperatively, showed a major benefit over enoxaparin, achieving an overall risk reduction of VTE greater than 50% without increasing the risk of clinically relevant bleeding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Roentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Noninvasive Diagnosis of Deep Venous Thrombosis
Kearon, C., Julian, J. A., Math, M., Newman, T. E., & Ginsberg, J. S. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-8-199804150-00011 · Cited by 690
Nurmohamed, M. T., Buller, H. R., Dekker, E., Hommes, D. W., Rosendaal, F. R., Briet, E., Rosendaal, F. R., & Vandenbroucke, J. P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93223-a · Cited by 668
Bauer, K. A., Eriksson, B. I., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011099 · Cited by 666
Self-citationEriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationTurpie, A. G., Bauer, K. A., Eriksson, B. I., & Lassen, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08648-8 · Cited by 537
Self-citationOlson, S. T., Björk, I., Sheffer, R., Craig, P. A., Shore, J. D., & Choay, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42309-5 · Cited by 470
The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics
van Boeckel, C. A. A., & Petitou, M. (1993) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199316713 · Cited by 382
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Dunn, A. S., & Kunz, R. (2012) · Chest · doi:10.1378/chest.11-2298 · Cited by 1,641
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citationComparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa055443 · Cited by 1,228
Heparin and Low-Molecular-Weight Heparin
Hirsh, J., Warkentin, T. E., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (1998) · Chest · doi:10.1378/chest.114.5_supplement.489s · Cited by 1,031
Cohen, A. T., Davidson, B. L., Gallus, A. S., Lassen, M. R., Prins, M. H., Tomkowski, W., Turpie, A. G. G., Egberts, J. F. M., & Lensing, A. W. A. (2006) · BMJ · doi:10.1136/bmj.38733.466748.7c · Cited by 857
Self-citationThe Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., & Ansell, J. (2008) · Chest · doi:10.1378/chest.08-0675 · Cited by 830
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Warkentin, T. E., Greinacher, A., Koster, A., & Lincoff, A. M. (2008) · Chest · doi:10.1378/chest.08-0677 · Cited by 816
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
Warkentin, T. E., & Greinacher, A. (2004) · Chest · doi:10.1378/chest.126.3_suppl.311s · Cited by 809
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Hornick, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62125-5 · Cited by 777
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Gogarten, W., Vandermeulen, E., Van Aken, H., Kozek, S., Llau, J. V., & Samama, C. M. (2010) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32833f6f6f · Cited by 529
Eriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522
Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials
Pildal, J., Hrobjartsson, A., Jorgensen, K., Hilden, J., Altman, D., & Gotzsche, P. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym087 · Cited by 472
Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs
Decousus, H., Prandoni, P., Mismetti, P., Bauersachs, R. M., Boda, Z., Brenner, B., Laporte, S., Matyas, L., Middeldorp, S., Sokurenko, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912072 · Cited by 402
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Eriksson, B. I. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.11.1337 · Cited by 345
Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F., & Schellong, S. (2007) · Circulation · doi:10.1161/circulationaha.106.668020 · Cited by 337
Agnelli, G., Bergqvist, D., Cohen, A. T., Gallus, A. S., & Gent, M. (2005) · British Journal of Surgery · doi:10.1002/bjs.5154 · Cited by 337
Douketis, J. D., Johnson, J. A., & Turpie, A. G. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.12.1319 · Cited by 328
Self-citationFrancis, C. W., Berkowitz, S. D., Comp, P. C., Lieberman, J. R., Ginsberg, J. S., Paiement, G., Peters, G. R., Roth, A. W., McElhattan, J., & Colwell, C. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035162 · Cited by 321
Crowther, M. A., & Warkentin, T. E. (2008) · Blood · doi:10.1182/blood-2007-10-120543 · Cited by 314
Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences*1
VILESGONZALEZ, J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.03.011 · Cited by 305
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., & Misselwitz, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3185 · Cited by 297
Stangier, J., Eriksson, B. I., Dahl, O. E., Ahnfelt, L., Nehmiz, G., Stähle, H., Rathgen, K., & Svärd, R. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274550 · Cited by 296
Incidence and cost burden of post-thrombotic syndrome
Ashrani, A. A., & Heit, J. A. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0309-3 · Cited by 295
Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines
Kietaibl, S., Ferrandis, R., Godier, A., Llau, J., Lobo, C., Macfarlane, A. J., Schlimp, C. J., Vandermeulen, E., Volk, T., von Heymann, C., et al. (2022) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001600 · Cited by 289
Weitz, J. I., Hirsh, J., & Samama, M. M. (2008) · Chest · doi:10.1378/chest.08-0673 · Cited by 262
Guidelines on the use and monitoring of heparin
Baglin, T., Barrowcliffe, T. W., Cohen, A., Greaves, M., & the British Committee for Standards in Haematology (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05953.x · Cited by 262
Steele, K. E., Canner, J., Prokopowicz, G., Verde, F., Beselman, A., Wyse, R., Chen, J., Streiff, M., Magnuson, T., Lidor, A., et al. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.10.003 · Cited by 54
Metadata
- Authors
- Turpie, A. G. G.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2002-09-09
- Volume
- 162
- Issue
- 16
- Pages
- 1833
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2098108939
- Cited by
- 736
- References
- 22
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.